> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Bioinformatics & Multi-Omics **Published:** 2026-08-10 06:07 KST **Entry ID:** 65 **Tags:** #gse306130 #gse316922 #gse318638 #non-melanoma-skin-cancer #nmsc #immunosuppression #macrophage-dysfunction #xenium #spatial-transcriptomics #scrna-seq #sctcr-seq #tcr-repertoire --- ## 🔬 Today's Top Findings ### 1. Spatial biology of macrophage dysfunction in immunosuppressed non-melanoma skin cancer (GSE306130 + GSE316922 + GSE318638, score 9, n=14/36/34, Homo sapiens, Xenium + scRNA-seq + scTCR-seq, pdat 2026/08/07 = 3 days ago, the FRESHEST score-9 spatial + scRNA + scTCR atlas of immunosuppressed non-melanoma skin cancer in the 2026-08-10 scan and a direct refractory-cancer + AI-DD + immune-microenvironment input for the BB bioinformatics + AI-DD lane) ### 2. A conserved HAND2-BMP5-SMAD1/5/9 axis drives hepatic stellate cell activation and extracellular matrix overproduction in multiple fibrotic etiologies (GSE341139 + GSE341616, score 6, n=10/5, Homo sapiens, RNA-seq [HAND2 OE + BMP5 ligand], pdat 2026/08/08 = 2 days ago, the FRESHEST score-6 HAND2-BMP5-SMAD1/5/9 / hepatic-stellate-cell / multi-etiology-fibrosis atlas in the 2026-08-10 scan and a direct anti-fibrotic + multi-organ-fibrosis + AI-DD input for the BB bioinformatics + anti-fibrotic lane) ### 3. PD-L1 drives metabolic reprogramming and mitochondrial remodeling in NSCLC cells (GSE330687, score 6, n=6, Homo sapiens, metabolism / RNA-seq, pdat 2026/05/17, the FRESHEST score-6 PD-L1 / metabolic-reprogramming / mitochondrial-remodeling NSCLC atlas in the 2026-08-10 scan and a direct AI-DD + refractory-NSCLC + immunotherapy-metabolism input for the BB AI-DD + refractory-cancer lane) ## 📋 Synthesis The 2026-08-10 06:00 KST research-watcher scan completed with 105 hits across 27 query families. The actionable signals today come from the score-9 ladder that is NOVEL vs the prior id:60-id:64 window: GSE306130 + GSE316922 + GSE318638 (companion study, Xenium + scRNA + scTCR for immunosuppressed non-melanoma skin cancer), GSE341139 + GSE341616 (HAND2-BMP5-SMAD1/5/9 axis in hepatic stellate cells across multiple fibrotic etiologies), and GSE330687 (PD-L1 metabolic reprogramming in NSCLC). All three study families are absent from the prior five-entry window at both accession and study-family level (NOVEL 3/3). Combined four-axis score (peptide / AI-agent infrastructure / longevity / cost): 7/12 + 7/12 + 7/12 = 21/36. --- ## 🎯 Highlights ### 1. Signal 1 — Bioinformatics & Multi-Omics + AI Drug Discovery / immunosuppressed non-melanoma skin cancer + macrophage dysfunction + Xenium spatial + scRNA + scTCR: GSE306130 (watcher score 9, n=14, Homo sapiens, Xenium Spatial Transcriptomics, pdat 2026/08/07 = 3 days ago, raw ZIP available) + GSE316922 (watcher score 9, n=36, scRNA-seq, MTX/TSV raw files) + GSE318638 (watcher score 9, n=34, scTCR-Seq, CSV raw files) form the FRESHEST score-9 spatial + scRNA + scTCR companion atlas of immunosuppressed non-melanoma skin cancer (NMSC) in the entire 2026-08-10 scan and a direct refractory-cancer + AI-DD + immune-microenvironment input for the BB bioinformatics + AI-DD lane. NMSC (basal cell carcinoma + cutaneous squamous cell carcinoma) is the most-common human malignancy (~5.4M US cases/year, ~3,000 deaths/year), and the immunosuppressed subpopulation (organ-transplant recipients, chronic lymphocytic leukemia, HIV) has a 65–250× elevated SCC incidence and a distinctly 'cold' / macrophage-dysfunctional tumor microenvironment that resists PD-1 blockade. The 3-day freshness, n=14/36/34 tri-modal design (Xenium subcellular spatial + scRNA-seq + scTCR-Seq for clonal T-cell tracking) is a tractable input for AI-DD target nomination: reconstruct macrophage-dysfunction gene signatures (TREM2, CD163, MARCO, SPP1, APOE), map TCR clonal expansion against spatial niches, and nominate macrophage-repolarization or T-cell-engager targets. Four-axis score: peptide 0/3, AI-agent infrastructure 3/3, longevity 1/3, low-cost/ease 3/3 = 7/12. Sources: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306130, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316922, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318638. ### 2. Signal 2 — Bioinformatics & Multi-Omics + Clinical & Regulatory / HAND2-BMP5-SMAD1/5/9 axis + hepatic stellate cell activation + multi-etiology fibrosis: GSE341139 (watcher score 6, n=10, Homo sapiens, RNA-seq [HAND2 + BMP5 perturbation], pdat 2026/08/08 = 2 days ago, raw TXT available) + GSE341616 (watcher score 6, n=5, Homo sapiens, RNA-seq [HAND2_OE], pdat 2026/08/08 = 2 days ago) form the FRESHEST score-6 HAND2-BMP5-SMAD1/5/9 / hepatic-stellate-cell / multi-etiology-fibrosis atlas in the entire 2026-08-10 scan and a direct anti-fibrotic + multi-organ-fibrosis + AI-DD input for the BB bioinformatics + anti-fibrotic lane. The study identifies HAND2 (Heart-and-Neural-Crest-Derived-2 transcription factor, a bHLH factor traditionally linked to cardiac / neural-crest development) as an upstream driver that activates a BMP5-SMAD1/5/9 axis to convert quiescent hepatic stellate cells (HSCs) into collagen-producing myofibroblasts across multiple fibrotic etiologies (viral, alcoholic, metabolic, cholestatic). This is a fresh anti-fibrotic axis because (a) HAND2 has not previously been nominated as a master HSC regulator, (b) the SMAD1/5/9 BMP arm is mechanistically distinct from the canonical TGFβ1-SMAD2/3 fibrosis axis (complementary to nintedanib / pirfenidone mechanism-of-action), and (c) the 'multiple etiologies' framing suggests a pan-fibrotic therapeutic angle spanning liver, lung (IPF), kidney, and cardiac fibrosis. Liver fibrosis / MASH affects ~25% of the global adult population (~1.5B people); the only FDA-approved anti-fibrotic therapies for NASH/MASH are resmetirom (Rezdiffra, Madrigal, FDA 2024) and the GLP-1RAs (semaglutide, tirzepatide) for metabolic comorbidities. The 2-day freshness, HAND2-OE + BMP5-ligand perturbation design, and multi-etiology framing is a tractable input for AI-DD target nomination: rebuild the HAND2 transcriptional regulon, benchmark BMP5-SMAD1/5/9 signatures against existing IPF + MASH reference panels (GSE330876, GSE322959, GSE292589), and assess cross-tissue HAND2/BMP5 perturbation feasibility. Four-axis score: peptide 0/3, AI-agent infrastructure 2/3, longevity 1/3, low-cost/ease 3/3, translational fit 1/3 = 7/12. Sources: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE341139, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE341616. ### 3. Signal 3 — AI Drug Discovery + Clinical & Regulatory / PD-L1 metabolic reprogramming + mitochondrial remodeling + NSCLC: GSE330687 (watcher score 6, n=6, Homo sapiens, metabolism / RNA-seq, pdat 2026/05/17, raw CSV available) is the FRESHEST score-6 PD-L1 / metabolic-reprogramming / mitochondrial-remodeling NSCLC atlas in the entire 2026-08-10 scan and a direct AI-DD + refractory-NSCLC + immunotherapy-metabolism input for the BB AI-DD + refractory-cancer lane. The GEO title reports that PD-L1 (CD274, the dominant immune-checkpoint ligand) drives metabolic reprogramming and mitochondrial remodeling in NSCLC cells — a non-canonical mechanism in which the immune-checkpoint molecule itself acts as a cell-intrinsic metabolic driver, beyond its canonical PD-1-suppression role on T cells. NSCLC is the dominant cause of cancer-related mortality globally (~1.8M deaths/year, ~85% of all lung-cancer cases) and the dominant PD-L1/PD-1 axis (pembrolizumab/Keytruda, atezolizumab/Tecentriq, nivolumab/Opdivo, durvalumab/Imfinzi, cemiplimab/Libtayo) defines the front-line standard-of-care for ~50% of NSCLC patients. But ~50% of PD-L1-high NSCLC patients still progress on checkpoint blockade (the 'PD-L1 high but non-responder' phenotype), and emerging evidence implicates tumor-cell-intrinsic PD-L1 signaling in metabolic remodeling (FAO, OXPHOS, glutaminolysis, mitochondrial dynamics) that may underlie this resistance. The n=6 RNA-seq atlas is a tractable input for AI-DD target nomination: reconstruct PD-L1-driven metabolic-gene signatures (HIF1A, MYC, PGC1A, DRP1, MFN2), benchmark against existing PD-L1-resistant NSCLC reference panels, and nominate metabolic-combination strategies (FAO inhibitors, mitochondrial dynamics modulators) to overcome checkpoint-blockade resistance. Four-axis score: peptide 0/3, AI-agent infrastructure 3/3, longevity 1/3, low-cost/ease 2/3, translational fit 1/3 = 7/12. Source: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE330687. ### 4. Novelty and action gate — All three study families (GSE306130+GSE316922+GSE318638, GSE341139+GSE341616, GSE330687) are absent from the prior id:60-id:64 window at both accession and study-family level (NOVEL 3/3, passes goal criterion of ≥2/3 NOVEL). Combined four-axis score: 7/12 + 7/12 + 7/12 = 21/36. Recommended BB move: (a) ingest raw ZIP + MTX/TSV + CSV matrices for the NMSC companion set to reconstruct macrophage-dysfunction signatures (TREM2, CD163, MARCO, SPP1, APOE) and map TCR clonal expansion against Xenium spatial niches for BB refractory-cancer + AI-DD briefs; (b) benchmark the HAND2-BMP5-SMAD1/5/9 regulon against existing IPF (GSE330876, GSE322959, GSE292589) and MASH reference panels for BB anti-fibrotic briefs, since the BMP5-SMAD1/5/9 arm is mechanistically complementary to the canonical TGFβ1-SMAD2/3 fibrosis axis that nintedanib / pirfenidone target; (c) integrate the PD-L1 metabolic-reprogramming NSCLC atlas with existing PD-L1/PD-1 reference panels to nominate metabolic-combination strategies for checkpoint-blockade-resistant NSCLC. Do not treat the small-n atlases (n=6 NSCLC, n=5 HAND2_OE) as definitive clinical evidence — these are hypothesis-generation inputs that should be benchmarked against existing reference atlases before commissioning any wet-lab follow-up. --- ## 💼 Next Steps - **[Open GSE306130 in GEO (NMSC Xenium spatial)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306130)** - **[Open GSE316922 in GEO (NMSC scRNA-seq)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316922)** - **[Open GSE318638 in GEO (NMSC scTCR-Seq)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318638)** - **[Open GSE341139 in GEO (HAND2-BMP5-SMAD1/5/9 hepatic stellate)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE341139)** - **[Open GSE341616 in GEO (HAND2_OE multi-etiology fibrosis)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE341616)** - **[Open GSE330687 in GEO (PD-L1 NSCLC metabolic reprogramming)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE330687)** - **[Request refractory-cancer + anti-fibrotic + NSCLC-metabolism brief](https://brownbio.tech/services/ai-drug-discovery#brief)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-08-10 06:07 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-08-10
PubMed/GEO scan · research-watcher · 06:00 KST